← Leaderboards
Ronald William Mink
Sedia Biosciences Corporation
$3,181,096
Attributed
$3,181,096
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2012–17$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$3,181,096 · 4
By mechanism
R44$2,791,483 · 2
R43$389,613 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Scale Up”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Eric S Lander · Whitehead Institute For Biomedical Res$494,464,719
- Richard K. Wilson · Washington University$429,146,711
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$404,701,805
- Richard A Gibbs · Baylor College Of Medicine$358,687,223
- David Heimbrook · Leidos Biomedical Research, Inc.$350,022,833
Research focus
Scale UpSpecimenProductionResearch PersonnelSerumSmall Business Innovation Research GrantEffectiveness Of InterventionsPerformanceEpidemiologistProgramsHiv-1InfectionIncidenceHiv InfectionsBaseCharacteristicsDiagnosticLaboratoriesCounselingEpidemicFollow-UpEvaluationCenters For Disease Control And Prevention (U.S.)Surveillance Program
Grant awards (5)
Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay$791,483
R44 · FY2017 · AI · contact PI
Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay$1,000,000
R44 · FY2016 · AI · contact PI
Novel Single Well Avidity EIA to Determine Recency of HIV-1 Infections$1,000,000
R44 · FY2014 · AI · contact PI
Development and Commercialization of an Innovative Rapid HIV-1 Incidence Assay$195,490
R43 · FY2014 · AI · contact PI
Novel Single Well Avidity EIA to Determine Recency of HIV-1 Infections$194,123
R43 · FY2012 · AI · contact PI